Formulation breakthroughs driving broader tyrosine kinase use

Documenti analoghi

• Severe Impact of Omeprazole Timing on pH‐Sensitive Dasatinib Absorption: Unveiling Substantial Drug–Drug Interaction
  di: Per Andersson, et al.
  Pubblicazione: (2024)
• Therapeutic drug monitoring—Does it really matter?
  di: Hans Lennernäs, et al.
  Pubblicazione: (2024)
• Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies
  di: Yuji Kumagai, et al.
  Pubblicazione: (2025)
• Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database
  di: Zeng‐Xiang Zhao, et al.
  Pubblicazione: (2024)
• Janus kinase inhibitors for the treatment of lichen Sclerosus: A systematic review
  di: Chin‐Hsuan Shen, et al.
  Pubblicazione: (2025)